Clinical Trials Browser

OTHER × Second Line Treatment of Gastric Cancer × camrelizumab × Clear all

NCT05669807 2023-01-03

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Second Line Treatment of Gastric Cancer